ADC Therapeutics (ADCT)
(Delayed Data from NYSE)
$4.30 USD
-0.27 (-5.91%)
Updated May 10, 2024 04:00 PM ET
After-Market: $4.29 -0.01 (-0.23%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Price, Consensus and EPS Surprise
ADCT 4.30 -0.27(-5.91%)
Will ADCT be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ADCT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ADCT
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Misses Revenue Estimates
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates
ADCT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Adobe (ADBE) to Report Q1 Earnings: What's in the Offing?
SentinelOne (S) to Report Q4 Earnings: What's in the Cards?
Zymeworks Inc. (ZYME) Reports Q4 Loss, Misses Revenue Estimates
Other News for ADCT
ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference
Insider Sale: CEO Ameet Mallik Sells 29,731 Shares of ADC Therapeutics SA (ADCT)
Buy Rating Affirmed for ADC Therapeutics on Strong Zynlonta Clinical Data and Strategic Growth Outlook
ADC Therapeutics (ADCT) Receives a Buy from RBC Capital
ADC Therapeutics price target lowered by $1 at H.C. Wainwright, here's why